Interim Chief Financial Officer reporting to Chief Operating Officer.

Independent Board Director, and member of the Audit Committee and Remuneration Committee, at Transgene (Euronext: TNG), headquartered near Strasbourg, France. Transgene is a clinical-stage biotechnology company focused on designing and developing novel immuno-therapeutics for the treatment of cancer. Transgene uses the mechanisms of immune response to enable the patient’s body to fight against disease, particularly, by integrating genetic sequences (or transgenes) into viral vectors to transform them into weapons that can kill abnormal cells.

Independent Board Director and Audit Committee Chairperson at Centessa, a public pharmaceutical company traded on NASDAQ and focused on delivering "asset-centricity" at scale. Centessa is a UK company that has international drug discovery & development operations.

Management and finance consulting firm focused on identifying and capitalizing on strategic growth opportunities, enhancing operational effectiveness, and increasing shareholder value. Serves as interim & part-time CFO for both private & public companies. Consulting experience includes the following companies:* Alpha II, LLC www.alphaii.com/ (sale of company to TA completed 8/16/23); * Cassiopea, Inc. www.cassiopea.com/ (sale of approved Rx Winlevi to Sun) ; * Kimberly-Clark, Inc. (Halyard Health spin-off to shareholders) www.kimberly-clark.com/; * Savara Pharmaceuticals www.savarapharma.com/; * BioClinica www.bioclinica.com/; * Pharmaceutical Regulatory Services, Inc. www.pharmregservices.com/

Interim Chief Financial Officer (CF0) reporting to CEO. Responsible for accounting, audit, strategic planning and analysis, tax, treasury, internal controls, budgeting. Led Due Diligence process in support of the successful sale of this private company to TA.

Independent Board Director and member of Audit Committee & Special Finance Committee at Epizyme, a commercial-stage biopharmaceutical company, traded on NASDAQ, that is committed to rewriting treatment for people with cancer through the discovery, development, and commercialization of novel epigenetic medicines. Epizyme was acquired by Ipsen on 8-12-2022 and ceased to be a separate public company on this date.

Independent Board Director, Audit Committee Chair and Compensation Committee Member of IPSEN, a public company headquartered in Paris, France. and traded on the EURONEXT (Paris, France) stock exchange. Nominated and approved by shareholders for two-four year terms of Board service.

CFO & Sr. VP Finance at Healthcare Payment Specialists, a fully owned subsidiary of TransUnion, Inc. Directed due diligence process with Investment Bankers & supported sale by Private Equity owner (Nautic Partners) to TransUnion. HPS offers value-added Medicare claims & cost report solutions, via SAAS or outsourced service.Scope: Financial analysis & reporting, strategic planning, accounting & controls, tax & treasury, gov't audit/reimbursement & Human Resources.* Designed & implemented automated, real-time Revenue Forecast model, consolidating contracted projects & probability adjusted new sales pipeline. Revenue is forecast by product, client & source.* Designed & implemented long term operations throughput model linked to the Revenue Forecast model. Real time updates as delivery or sales close dates are revised. Ops model supports operational capacity planning requirements, consistent with & linked to the Revenue Forecast Model.* Designed & implemented Total Sales Contract Value to Cash to Revenue model, linking multi-year contract values to invoicing & revenue recognition dates. This model enables the synchronization of annual sales goals & revenue goals, & projects the cash & revenue streams associated with each contract. * Transformed financial reporting from Employee/non-employee expense P&L presentation to traditional Cost of Revenues, R&D and S,G&A financial reporting. Implemented monthly departmental P&L reporting, increasing transparency & accountability while enhancing decision making. Created Segment P&Ls for public company reporting purposes.* Transitioned HPS to new banking partner with higher yields (nightly investment sweep) & drove migration from physical checks to ACH payments, while increasing security (debit blocks and positive pay).* Transitioned 401k Plan to new Record Keeper & Advisor.* Drove change in application of GAAP revenue recognition accounting in accordance with the continued evolution of the business & GAAP standards.

Financial management consulting firm (CFO level) focused on identifying and capitalizing on strategic growth opportunities, enhancing operational effectiveness, driving organizational alignment and increasing shareholder value. Also self employed management consulting firm.* Kimberly-Clark Corp (KMB). - Spin-off of Health Care business unit (Halyard Health Inc. - SEC Form 10) to KMB public shareholders. Responsible for preparing spin-off Accounting/Finance Playbook, creating a cross-functional global Restructuring Step Plan and providing related guidance to subsidiary finance teams..* Savara Pharmaceuticals - Private company IPO gap evaluation (SEC S-1 & Form 10 filing alternatives), including financial controls, management reporting, board composition, policies & procedures, etc.

Specialty Pharmaceutical & Consumer Healthcare Company (Nestle & L'Oreal Joint Venture, currently a Nestle Skin Health Company)Scope: North American CFO, VP Finance; Accounting, Financial Reporting, Internal Controls, Financial Planning & Analysis, Tax Planning & Compliance, Treasury, Credit, Procurement/Purchasing, Government Pricing & Reporting Compliance, Transactions Processing (Accounts Payable, Accounts Receivable, Travel Expense & Payroll).• Drove organizational goal alignment toward Net Sales & Profit optimization from prior Sales unit focus.• Improved cash flow by $10M+ per year via contract term negotiations, EFT conversions & implementation / monitoring of goals.• Designed & implemented legal entity reorganization strategy; $4M+ immediate cash tax savings.• Remedied internal control deficiencies & earned “Satisfactory” audit rating vs. prior “Needs Improvement” audit rating.• Implemented Purchasing policy & RFP approval processes; negotiated 2012 savings of $2.8M.* Built FP&A team; developed business analytics, pricing review models, contract review processes & metrics; & product/business acquisition & valuation models.

2007 Global Revenue: $48 billionScope: International Treasury (foreign exchange, liquidity management, capital structure, dividend planning, global banking relationships), US Accounts Receivable/Cash Applications, US Credit & Collections, & US Treasury Operations (including Commercial Paper). • Co-planned & executed $40 billion Homeland Investment Act repatriation ($8B tax savings).• Co-led integration of Pharmacia’s Treasury organization, ensuring best practices & exceeding expense savings targets. • Designed & implemented strategies reducing global currency exposures (~$5B savings).• Planned & executed Treasury aspects of global acquisitions/divestitures; Consumer Healthcare divestiture ($16.6B), Adams confectionary ($4.2B), etc. • Planned & implemented Financial Shared Service migration of US Accounts Receivable & Credit & Collections, surpassing savings targets by 20% while maintaining high customer satisfaction & service levels. • Supported sales growth with new Credit Scoring Model, reduced customer inventories & payment terms.

2002 North American Revenue: $2.0 billion (post Warner-Lambert acquisition). Scope: North American CFO, VP Finance & Leadership team member, accounting, management reporting, financial controls, financial planning & analysis, forecasting, strategic business reviews & product acquisitions/divestitures. • Key Leader of 6-member global CHC Integration Steering Committee (Warner-Lambert); delivered in excess of $47 million synergy savings while growing the business & transforming corporate culture.• Key Leader of Finance Integration Steering Committee (new chart of accounts) & CHC representative on Pfizer Integration Coordination Committee, ensuring smooth business integrations & savings target achievement.• Recruited, trained & developed new regional finance team; focused on analytics & strategic business support. • Led transition to Pfizer policies, procedures & systems, including conversion from SAP.

1999 Global Revenue: $0.6 billion (pre Warner-Lambert acquisition)Scope: Global CFO, VP Finance including IT, financial planning & analysis, management reporting, strategic planning, portfolio planning, forecasting, product acquisitions & divestitures, manufacturing & R&D finance. • Restructured headquarters finance organization with emphasis on standardized Hyperion system solutions, enhanced analytical & strategic business support & improved reporting/forecasting capabilities.• Key leader of business reengineering with strategic realignment on Rx to OTC switches. • Successfully managed Y2K with zero disruptions; designed & implemented customer P&Ls.

1997 Global Revenue: $1.5 billion. Scope: Global Divisional CFO, VP Finance with emphasis on financial planning & analysis, forecasting, management reporting, restructuring & divesting the Medical Device businesses. Global VP Finance, CFO for four global medical device businesses prior to divestiture.• Successfully divested Schneider ($2.1 bill.), Howmedica ($1.7 bill.), Valleylab & AMS global medical device businesses.• Led transformation of global consolidation process from spreadsheet-based to centralized Hyperion solution. Implemented standardized currency adjusted reporting metrics.• Revamped planning & analysis team, improved reporting & forecasting & drove strategic business growth.• Drove global transfer pricing study, implemented transfer price changes & delivered significant tax savings.

1997 European Region Revenue: $2.1 billion.Scope: European CFO role focused on financial planning & analysis, management reporting, business strategy & partnership negotiations (co-marketing, co-promotion), business reviews, manufacturing rationalization strategy & tax planning. European Region included Western & Eastern Europe, Africa, Middle East & Canada. Businesses included pharmaceuticals, animal health products & consumer healthcare products.Additional Job Titles:Director Finance (CFO) - Europe (1990 – 1995)Associate & Assistant Director Finance (CFO) - Europe (1987 – 1990)Projects Manager - Europe/AFME (1985 – 1987)Financial Analyst - Europe/AFME (1984 – 1985)• Delivered $43 million tax savings in 3 years by creating & implementing new product sourcing strategy.• Designed & executed new business strategy to grow $60 million German-HQ branded-generics business.• Planned & executed European manufacturing rationalization strategy, reducing # of dosage form plants from 9 to 4. • Engineered & implemented pharmaceutical profit maximization strategies for the UK, France & Turkey (government profit control legislation). • Led product co-marketing, co-promotion & licensing strategies & analyses. Monitored parallel trade.• Established global intercompany royalty rates in accordance with IRS comparables for key brands (Norvasc, Cardura & Diflucan).• Designed & implemented metrics-based executive bonus compensation model (transitioned from salary to salary and at risk bonus compensation plan).* Lobbied Irish Finance Minster, as one of four pharmaceutical industry representatives, to hold corporate tax rates at 10%.